Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients

Breast

Volumn 23, Issue 5, 2014, Pages 637-643

  Berghoff, Anna S ^a,b   Bartsch, Rupert ^b   Preusser, Matthias ^b   Ricken, Gerda ^a,b   Steger, Guenther G ^b   Bago Horvath, Zsuzsanna ^b   Rudas, Margareta ^b   Streubel, Berthold ^c   Dubsky, Peter ^b   Gnant, Michael ^b   Fitzal, Florian ^b   Zielinski, Christoph C ^b   Birner, Peter ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

Author keywords

Breast cancer; HER2 positive; HER3; Trastuzumab

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TRASTUZUMAB; ERBB2 PROTEIN, HUMAN; ERBB3 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER CLASSIFICATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DIMERIZATION; DISEASE COURSE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HER2 GENE; HER3 GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL TIME; VISCERAL METASTASIS; BRAIN TUMOR; BREAST TUMOR; DIGESTIVE SYSTEM TUMOR; FEMALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; BREAST NEOPLASMS; DIGESTIVE SYSTEM NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84908216580     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2014.06.011     Document Type: Article

References (44)

1. Berry D.A., Cronin K.A., Plevritis S.K., Fryback D.G., Clarke L., Zelen M., et al. Effect of screening and adjuvant therapy on mortality from breast cancer. New Engl J Med 2005, 353(17):1784-1792.
2. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., et al. Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752.
3. Tran B., Bedard P.L. Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res BCR 2011, 13(6):221.
4. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235(4785):177-182.
5. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med 2001, 344(11):783-792.
6. Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. New Engl J Med 2006, 355(26):2733-2743.
7. Verma S., Miles D., Gianni L., Krop I.E., Welslau M., Baselga J., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. New Engl J Med 2012, 367(19):1783-1791.
8. Lin N.U., Thomssen C., Cardoso F., Cameron D., Cufer T., Fallowfield L., et al. International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC task force: surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. Breast 2013, 22(3):203-210.
9. Lin N.U., Winer E.P. Brain metastases: the HER2 paradigm. Clin Cancer Res Off J Am Assoc Cancer Res 2007, 13(6):1648-1655.
10. Bartsch R., Ziebermayr R., Zielinski C.C., Steger G.G. Triple-negative breast cancer. Wiener medizinische Wochenschrift 2010, 160(7-8):174-181.
11. Zaczek A., Brandt B., Bielawski K.P. The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. Histol Histopathol 2005, 20(3):1005-1015.
12. Aceto N., Duss S., Macdonald G., Meyer D.S., Roloff T.C., Hynes N.E., et al. Co-expression of HER2 and HER3 receptor tyrosine kinases enhances invasion of breast cells via stimulation of interleukin-8 autocrine secretion. Breast Cancer Res BCR 2012, 14(5):R131.
13. Garrett J.T., Sutton C.R., Kuba M.G., Cook R.S., Arteaga C.L. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function. Clin Cancer Res Off J Am Assoc Cancer Res 2013, 19(3):610-619.
14. Sergina N.V., Rausch M., Wang D., Blair J., Hann B., Shokat K.M., et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007, 445(7126):437-441.
15. Chen F.L., Xia W., Spector N.L. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors. Clin Cancer Res Off J Am Assoc Cancer Res 2008, 14(21):6730-6734.
16. Bae S.Y., La Choi Y., Kim S., Kim M., Kim J., Jung S.P., et al. HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients. Breast Cancer Res Treat 2013.
17. Da Silva L., Simpson P.T., Smart C.E., Cocciardi S., Waddell N., Lane A., et al. HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Res BCR 2010, 12(4):R46.
18. Hammond M.E., Hayes D.F., Wolff A.C. Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 2011, 29(15):e458.
19. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007, 131(1):18-43.
20. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 2007, 25(1):118-145.
21. Spitale A., Mazzola P., Soldini D., Mazzucchelli L., Bordoni A. Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol Off J Eur Soc Med Oncol/ESMO 2009, 20(4):628-635.
22. Sotiriou C., Pusztai L. Gene-expression signatures in breast cancer. New Engl J Med 2009, 360(8):790-800.
23. Cancer Genome Atlas, N Comprehensive molecular portraits of human breast tumours. Nature 2012, 490(7418):61-70.
24. Bender R., Lange S. Adjusting for multiple testing-when and how?. J Clin Epidemiol 2001, 54(4):343-349.
25. Lemoine N.R., Barnes D.M., Hollywood D.P., Hughes C.M., Smith P., Dublin E., et al. Expression of the ERBB3 gene product in breast cancer. Br J Cancer 1992, 66(6):1116-1121.
26. Travis A., Pinder S.E., Robertson J.F., Bell J.A., Wencyk P., Gullick W.J., et al. C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br J Cancer 1996, 74(2):229-233.
27. Chiu C.G., Masoudi H., Leung S., Voduc D.K., Gilks B., Huntsman D.G., et al. HER-3 overexpression is prognostic of reduced breast cancer survival: a study of 4046 patients. Ann Surg 2010, 251(6):1107-1116.
28. Witton C.J., Reeves J.R., Going J.J., Cooke T.G., Bartlett J.M. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003, 200(3):290-297.
29. Wiseman S.M., Makretsov N., Nielsen T.O., Gilks B., Yorida E., Cheang M., et al. Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer 2005, 103(9):1770-1777.
30. Garrett J.T., Olivares M.G., Rinehart C., Granja-Ingram N.D., Sanchez V., Chakrabarty A., et al. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci U S A 2011, 108(12):5021-5026.
31. Lee-Hoeflich S.T., Crocker L., Yao E., Pham T., Munroe X., Hoeflich K.P., et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008, 68(14):5878-5887.
32. Hsieh A.C., Moasser M.M. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 2007, 97(4):453-457.
33. Holbro T., Beerli R.R., Maurer F., Koziczak M., Barbas C.F., Hynes N.E. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A 2003, 100(15):8933-8938.
34. Swain S.M., Kim S.B., Cortes J., Ro J., Semiglazov V., Campone M., et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013, 14(6):461-471.
35. Gelmon K., Fumoleau P., Verma S., Wardley A., Conte P., Miles D., et al. Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy. J Clin Oncol 2008, 26(Suppl. 15). Abst 1026.
36. Gutteridge E., Agrawal A., Nicholson R., Leung Cheung K., Robertson J., Gee J. The effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: a phase II study. Int J Cancer J Int du Cancer 2010, 126(8):1806-1816.
37. Clayton A.J., Danson S., Jolly S., Ryder W.D., Burt P.A., Stewart A.L., et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004, 91(4):639-643.
38. Bartsch R., Berghoff A., Pluschnig U., Bago-Horvath Z., Dubsky P., Rottenfusser A., et al. Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases. Br J Cancer 2012, 106(1):25-31.
39. Bartsch R., Berghoff A.S., Preusser M. Optimal management of brain metastases from breast cancer. Issues and considerations. CNS Drugs 2013, 27(2):121-134.
40. Bartsch R., Rottenfusser A., Wenzel C., Dieckmann K., Pluschnig U., Altorjai G., et al. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J Neuro-oncol 2007, 85(3):311-317.
41. Birner P., Oberhuber G., Stani J., Reithofer C., Samonigg H., Hausmaninger H., et al. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res 2001, 7(6):1669-1675.
42. Pivot X., Semiglazov V., Zurawski B., Allerton R., Fabi A., Ciruelos E., et al. CEREBEL (EGF111438): an open label randomized phase III study comparing the incidence of CNS metastases in patients (pts) with HER2+ Metastatic Breast Cancer (MBC), treated with Lapatinib plus Capecitabine (LC) versus Trastuzumab plus Capecitabine (TC). Presented at ESMO 2012, Vienna: p. LBA11 2012.
43. Moeder C.B., Giltnane J.M., Harigopal M., Molinaro A., Robinson A., Gelmon K., et al. Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. J Clin Oncol Off J Am Soc Clin Onc 2007, 25(34):5418-5425.
44. Duchnowska R., Dziadziuszko R., Trojanowski T., Mandat T., Och W., Czartoryska-Arlukowicz B., et al. Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain. Breast Cancer Res BCR 2012, 14(4):R119.